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Sterol regulatory element binding proteins (SREBPs)
are transcription factors that activate transcription
of the genes involved in cholesterol and fatty acid
biosynthesis. In the present study, we show that
a small synthetic molecule we previously discovered
to block adipogenesis is an inhibitor of the SREBP
activation. The diarylthiazole derivative, now called
fatostatin, impairs the activation process of SREBPs,
thereby decreasing the transcription of lipogenic
genes in cells. Our analysis suggests that fatostatin
inhibits the ER-Golgi translocation of SREBPs
through binding to their escort protein, the SREBP
cleavage-activating protein (SCAP), at a distinct site
from the sterol-binding domain. Fatostatin blocked
increases in bodyweight, blood glucose, and hepatic
fat accumulation in obese ob/ob mice, even under
uncontrolled food intake. Fatostatin may serve as
a tool for gaining further insights into the regulation
of SREBP.
INTRODUCTION
Metabolic syndrome is often ascribed to the long-term intake of
excess diets rich in fat or carbohydrates. The amount of fat or
carbohydrates in the diets of animals, including humans, contrib-
utes significantly to their energy metabolism. Long-chain fatty
acids are major sources of energy and important components
of the lipids that comprise the cellular membrane (Gibbons,
2003). They are either derived from food or synthesized de
novo from acetyl-CoA through complex sets of enzymatic reac-
tions— namely, lipogenesis—that involve the conversion of glu-
cose into acylglycerides (Gibbons, 2003; Wakil, 1989). These
reactions include glycolysis and the citric acid cycle, which
collectively lead to the formation of the backbone carbons of
fatty acids and glycerols for the synthesis of lipids.
Transcription factors SREBP-1a, SREBP-1c, and SREBP-2
are major regulators of genes encoding enzymes in lipogenic
pathways (Brown and Goldstein, 1997; Osborne, 2000). SREBPs882 Chemistry & Biology 16, 882–892, August 28, 2009 ª2009 Elsevare synthesized as ER-membrane-bound precursors; they must
be proteolytically released by two proteases bound to the Golgi
membrane, Site-1 (S1P) and Site-2 (S2P) proteases, to generate
an active form that activates transcription of target genes in the
nucleus (Brown and Goldstein, 1997; Sakai et al., 1996). The
proteolytic activation of SREBPs is tightly regulated by sterols
through interaction with the SREBP cleavage-activating protein
(SCAP), an ER-membrane-bound escort protein of SREBPs
(Goldstein et al., 2006; Hua et al., 1996). When sterols accumu-
late in the ER membranes, the SCAP/SREBP complex fails to
exit the ER to the Golgi apparatus, and the proteolytic process-
ing of SREBPs is suppressed. Thus, SREBPs are key lipogenic
transcription factors that govern the homeostasis of fat metabo-
lism.
We previously discovered a small organic molecule, formerly
called 125B11, which we now call fatostatin (Figure 1A); this
molecule inhibited the insulin-induced adipogenesis of 3T3-L1
cells and the serum-independent growth of human androgen-
independent prostate cancer (DU145) cells (Choi et al., 2003).
Results of the present study show that fatostatin blocks the acti-
vation of SREBPs in cells in tissue culture. Furthermore, we show
that fatostatin reduced adiposity, ameliorated fatty liver by
reducing triglyceride (TG) storage, and lowered hyperglycemia
in ob/ob mice.
RESULTS
Fatostatin Reduces Expression of SREBP-Responsive
Genes
To gain information about specific molecular pathways affected
by fatostatin, gene expression profiles of drug-treated and
untreated cells were compared. DU145 cells were treated with
fatostatin or DMSO alone, and the extracted mRNA samples
were analyzed by Affymetrix DNA microarrays mapping 33,000
genes. Of these genes, transcription levels of 63 genes de-
creased by at least 35% in response to fatostatin treatment
(see Figure S1 available online). Thirty-four of the affected
genes—such as those encoding biosynthetic enzymes—were
directly associated with fat or sterol synthesis; 18 of the affected
genes have been reported to be controlled by SREBPs (Horton
et al., 2003a). Down-regulation of the affected SREBP-respon-
sive genes was confirmed by RT-PCR experiments (Figures 1Bier Ltd All rights reserved
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Figure 1. Fatostatin Blocks Activation of
SREBP
(A) Structure of fatostatin.
(B) Down-regulation of affected genes confirmed
by RT-PCR. DU145 cells were treated with DMSO
(lane 1) or 5 mM fatostatin (lane 2) for 6 hr. Total
RNA was then extracted and subjected to RT-
PCR for ATP citrate lyase (ACL), 3-hydroxy-3-
methyl-glutaryl-CoA reductase (HMG-CoAR), low-
density lipoprotein receptor (LDLR), mevalonate
pyrophosphate decarboxylase (MVD), stearoyl-
CoA desaturase (SCD1), insulin-induced gene 1
(INSIG-1), and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH).
(C) Decrease in selected genes, shown in microar-
ray analyses and confirmed by decreases in their
RT-PCR measurements, caused by treatment
with fatostatin.
(D) Suppression by fatostatin of ability of endoge-
nous SREBPs to activate transcription of reporter
gene. CHO-K1 cells were transfected with a
reporter gene, in which the expression of luciferase
was controlled by three repeats of sterol-respon-
sive elements (SREs) (pSRE-Luc) and treated by
varied concentrations of fatostatin in a medium
containing lipid-free serum. Values are the mean ±
SD (n = 3).
(E) Effect of fatostatin (20 mM) on CHO-K1 cells
cotransfected with pCMV-SREBP-1c(1-436) and
pSRE-Luc in amedium containing lipid-free serum.
Values are the mean ± SD (n = 3).
(F) PLAP-BP2 in transfected CHO-K1 cells remains
membrane-bound, unless it is cleavedbyS1P in the
Golgi apparatus and secreted into the culture
medium. Compared with EtOH controls, treatment
with fatostatin (20 mM) or sterols (10 mg/mL choles-
terol and 1 mg/mL 25-hydroxycholesterol) affects
cleavage of PLAP-BP2. Values are the mean ± SD
(n = 3).
(G) Western blot analysis of CHO-K1 cells treated
with fatostatin. P and N denote the uncleaved
membrane precursor and cleaved active nuclear
forms of SREBP-2, respectively.and 1C). The high occurrence among the down-regulated genes
of the known SREBP-responsive genes and fat/cholesterol
biosynthesis genes implies that fatostatin acts either directly or
indirectly on the SREBP pathway.
Fatostatin Blocks Proteolytic Activation of SREBPs
To confirm that fatostatin acts on the SREBP pathway, the ability
of endogenous SREBPs to activate the transcription of an
SREBP-responsive reporter gene was measured in Chinese
hamster ovary-K1 (CHO-K1) cells in either the presence or the
absence of fatostatin. Fatostatin decreased activation of the
reporter gene, in which the expression of luciferase is controlled
by three repeats of sterol regulatory elements (SREs) (pSRE-
Luc; Figure 1D). We also analyzed the effects of fatostatin on
gene activation by an exogenously expressed mature form of
SREBP-1 (amino acids 1–436), a constitutively active form of
SREBP. Fatostatin had a limited effect on the ability of the
mature form of SREBP to activate the reporter gene (Figure 1E).
Collectively, these results suggest that fatostatin impairs the
activation process of SREBPs.Chemistry & Biology 16, 8To determine whether fatostatin affects the ER-Golgi translo-
cation and proteolytic processing of SREBPs, we used a reporter
assay developed by Sakai et al. (1998a). In this assay, a secreted
alkaline phosphatase, fused with an SREBP-2 fragment lacking
the NH2-terminal DNA-binding domain (PLAP-BP2513–1141),
permits monitoring of translocation and processing through
changes in the fluorescence of a fluorogenic phosphatase sub-
strate (Figure 1F). When cells were cotransfected with plasmids
encoding PLAP-BP2513–1141 and SCAP, PLAP phosphatase
was secreted and fluorescence signals were generated. Secre-
tion was similarly decreased by the addition of either fatostatin
or sterols (Figure1F). The fatostatin-mediated inhibitionofSREBP
activation was confirmed by Western blot analysis of SREBPs.
Treatment of the CHO-K1 cells with fatostatin decreased the
amount of the 68 kDa mature nuclear active form N of SREBP-2
and increased the amount of the 125 kDa precursor form P of
SREBP-2 (Figure 1G). Similar resultswere obtained for SREBP-1;
the nuclear active form N is reduced in the presence of fatostatin
(Figure S2). These results collectively suggest that fatostatin
blocks the activation process of both isoforms of SREBP.82–892, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 883
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A Small Molecule That Blocks Fat SynthesisFatostatin Inhibits Translocation of SCAP from ER
to Golgi Apparatus
We hypothesized that fatostatin impairs either the proteolytic
cleavage of SREBPs in the Golgi apparatus or the ER-to-Golgi
translocation of theSCAP/SREBPcomplex. BrefeldinA, a natural
product that blocks anterograde movement of proteins from the
ER to the Golgi, is known to render SREBPs unresponsive to
sterols; it causes SREBPs to be constitutively processed in the
ER by relocating S1P from the Golgi to the ER (DeBose-Boyd
et al., 1999). In the presence of brefeldin A, fatostatin, like sterols,
had no impact on the SREBP processing, as shown by the
formation of the proteolytic products (N) in the CHO-K1 cells
(Figure 2A), suggesting that fatostatin does not block the prote-
olysis itself.
The translocated SCAP has higher levels of glycosylation, and
it is more resistant to endoglycosidase H than is ER-bound
SCAP. Inhibiting the ER-to-Golgi translocation of SCAP by
sterols increases the sensitivity of SCAP to endoglycosidase H
(Figure 2B) (Nohturfft et al., 1998). To determine whether fatosta-
tin blocks the ER-to-Golgi translocation of the SCAP/SREBP
complex, thus increasing SCAP sensitivity to endoglycosidase
H, we analyzed the extent of N-linked glycosylation of SCAP in
the Golgi apparatus. Cells were grown in the absence or pres-
ence of fatostatin or sterols, and membrane fractions were
treated successively with trypsin and endoglycosidase H. In cells
grown without fatostatin and sterols, a tryptic fragment of SCAP
was more resistant to endoglycosidase H and had one or two
saccharide chains (Figure 2C, lane 1). In contrast, when cells
were grown in the presence of fatostatin or sterols, the SCAP
fragment was less resistant to endoglycosidase H and had either
zero or one saccharide chain (Figure 2C, lanes 2 and 3). There-
fore, like sterols, fatostatin appears to inhibit the translocation
of SCAP from the ER to the Golgi.
Fatostatin Interacts with SCAP
Studies of the relationship of structure and activity in fatostatin
indicated that this molecule retains or even increases biological
activity when its toluene moiety is modified with a variety of alkyl
or aryl sulfonamide groups (unpublished data). One fluorescent
derivative, dansyl fatostatin (Figure 3A), retained the ability to
block SREBP activation (Figures S3–S5) and served as a micro-
scopic probe. Confocal microscopic analyses revealed that
the localization of dansyl fatostatin overlapped with that of ER-
tracker red, a specific marker for ER (Figure 3B). In contrast,
the control dansyl molecule—which lacked fatostatin—failed to
localize to any organelle (data not shown). The selective ER
localization implies that fatostatin binds to a protein in the ER;
the most likely candidate is SCAP, the target of cholesterol for
the control of SREBP (Radhakrishnan et al., 2004). To test this
hypothesis, proteins bound to a fatostatin-polyproline linker-
biotin conjugate (Figure 3A and Figure S3) (Sato et al., 2007)
were purified from cell lysates and analyzed by Western blots
with antibodies against SCAP, SREBP-1, SREBP-2, and HMG-
CoAR, as well as ATF6, an unrelated ER-bound transcription
factor (Ye et al., 2000). The results suggest that fatostatin binds
directly or indirectly to SCAP (Figure 3C). The interaction was
impaired by adding excess amounts of fatostatin but not choles-
terol (Figure 3D). The conjugate 4 that lacks fatostatin failed to
bind to SCAP (Figure 3C).884 Chemistry & Biology 16, 882–892, August 28, 2009 ª2009 ElsevTo examine whether fatostatin interacts with SCAP directly,
we synthesized a fatostatin derivative coupled with a photo-
active diazirine group and a biotin molecule (conjugate 5, Fig-
ure 4A and Figure S4). This fatostatin conjugate is still as active
as fatostatin in reporter gene assays (Figure S5) and allows cova-
lent cross-linking of the biotinylated molecule with its target
protein upon UV irradiation. FLAG-tagged full-length SCAP
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Figure 2. Fatostatin Blocks Translocation of SREBPs from ER to
Golgi
(A) Western blot analysis showing effects of brefeldin A (1 mg/mL) on CHO-K1
cells treated with EtOH alone, or EtOH containing fatostatin (20 mM), or sterols
(10 mg/ml cholesterol and 1 mg/ml 25-hydroxycholesterol). (P andN are defined
in the Figure 1 legend.)
(B) SCAP contains a glycosylated luminal loop, which is protected from prote-
olysis by trypsin and which recognizes anti-SCAP IgG-9D5. When SCAP
resides in the ER, the two oligosaccharides in the loop are sensitive to endo-
glycosidase H. As SCAP is transported to the Golgi apparatus, its sugars
become resistant to digestion by endoglycosidase H.
(C) Western blot analysis with anti-SCAP IgG-9D5 of cells grown in the
absence or presence of fatostatin (20 mM) or sterols (10 mg/mL cholesterol
and 1 mg/mL 25-hydroxycholesterol). Numbers on the right denote the number
of N-linked sugar chains present on protease-protected SCAP fragments.ier Ltd All rights reserved
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A Small Molecule That Blocks Fat Synthesisprotein (amino acids 1–1276) was expressed in human embry-
onic kidney (HEK) 293T cells and immunopurified with a FLAG
antibody. The partially purified SCAP protein was incubated
with conjugate 5 and irradiated by UV to allow cross-linking.
The Western blot analysis of the products using streptavidin-
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Figure 3. Fatostatin Interacts with SCAP
(A) The structures of dansyl fatostatin and fatostatin-
polyproline linker-biotin conjugate. The polyproline
linker was inserted for better projection of the fatos-
tatin molecule (Sato et al., 2007).
(B) CHO-K1 cells treated with dansyl fatostatin and
ER-tracker red showing localization of dansyl fatos-
tatin in the ER. Scale bar = 10 mm.
(C) Interaction of fatostatin-polyproline linker-biotin
conjugate 3 with SCAP. Proteins bound to Neutravi-
dine-agarose beads saturated with fatostatin-poly-
proline linker-biotin conjugate 3 were isolated from
CHO-K1 membrane extracts, and then analyzed by
Western blots with anti-SCAP, anti-SREBP-1, anti-
SREBP-2, anti-HMG-CoAR, and anti-ATF6 anti-
bodies. SCAP was the only protein that interacted
with conjugate 3. Control experiments with polypro-
line linker-biotin conjugate 4 that did not contain
fatostatin gave negative results.
(D) For the competition assay, membrane extracts
were preincubated with EtOH alone, cholesterol, or
fatostatin.
HRP or a FLAG antibody showed a biotiny-
lated protein band whose electrophoretic
mobility matches that of full-length SCAP
(Figure 4B). Without UV irradiation, this
band was undetectable (Figure S6), indi-
cating that the interaction of fatostatin
with SCAP is reversible. A FLAG-tagged
NH2-terminal fragments of SCAP (amino
acids 1–415 and 1–448), which include a
binding site for sterols, failed to cross-link
to fatostatin conjugate 5 (Figure 4B). These
results suggest that fatostatin directly inter-
acts with SCAP at a site distinct from the
sterol-binding domain.
Sterols are known to induce the interac-
tion of SCAP with ER-bound INSIG pro-
teins, thereby inhibiting the exit of SCAP
from ER (Yang et al., 2002; Yabe et al.,
2002). To examine whether fatostatin
similarly induces the SCAP-INSIG interac-
tion, we performed coimmunoprecipitation
experiments with cells expressing Myc-
tagged INSIG-1. The results showed that
Myc-tagged INSIG-1 binds SCAP in the
presence of sterols but not in the presence
of fatostatin, even at high concentrations
(Figure 5). These results suggest that both
sterols and fatostatin modulate the function
of SCAP, but their mechanisms may be
distinct from each other.
One remaining possibility is that fatosta-
tin may inhibit the interaction of SCAP
with SREBPs. We examined whether conjugate 5 binds to
a COOH-terminal domain of SCAP (amino acids 732–1276),
which includes SREBP-binding domain (Sakai et al., 1998b).
The results showed that conjugate 5 failed to interact with the
COOH-terminal domain of SCAP, whereas the other half ofChemistry & Biology 16, 882–892, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 885
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A Small Molecule That Blocks Fat SynthesisSCAP (amino acids 1-767) reacted with conjugate 5 (Figure 4B).
Consistent with this observation, when we conducted coimmu-
noprecipitation experiments with HSV-tagged SREBP-2 (Fig-
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Figure 4. Direct Interaction of Fatostatin
with SCAP
(A) The structure of conjugate 5.
(B) Conjugate 5-cross-linked proteins. FLAG-
tagged full-length SCAP (amino acids 1–1276) and
fragments of SCAP (amino acids 1–415, 1–448,
1–767, and 732–1276) proteins were expressed
in 293T cells and immunoprecipitated with a
FLAG antibody. Conjugate 5-cross-linked proteins
were detected by streptavidin-HRP (left) or a FLAG
antibody (right). The asterisk denotes a FLAG anti-
body used for the immunoprecipitation.
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Figure 5. Coimmunoprecipitation of INSIG-1 with SCAP
CHO-K1 cells expressing Myc-tagged INSIG-1 were treated with EtOH alone,
or EtOH containing fatostatin (20 mM), or sterols (10 mg/ml cholesterol and
1 mg/ml 25-hydroxycholesterol). The cells were harvested, lysed, and immuno-
precipitated with anti-Myc antibody to precipitate INSIG-1. Pellets were sub-
jected to Western blot analysis with anti-SCAP and anti-Myc antibodies.
ure S7), fatostatin had no impact on the
binding between SREBP-2 and SCAP.
Effects of Fatostatin on ob/ob
Mice—Body Weight, Blood
Constituents, and Liver
and Adipose Tissues
Having established a key role of SREBPs
in lipogenesis, we then examined the
pharmacological effects of fatostatin on
ob/ob mice, a mouse model of obesity
with uncontrolled food intake. Fatostatin
was delivered intraperitoneally daily for
28 days, and food intake and body weight
were monitored. The average daily food
intake of the treated mice was not signifi-
cantly different from that of the controls
(5.4 ± 1.5 versus 5.9 ± 1.4 g/mouse/day,
respectively), and no obvious toxicity
was observed during the treatment (Figures 6A and 6B). Fol-
lowing four weeks’ treatment with fatostatin, the mice weighed
approximately 12% less than the untreated controls (32.1 ± 1.4
and 36.2 ± 2.2 g/mouse, respectively; p = 0.02). One of the
most distinct phenotypes in ob/ob mice is hyperglycemia re-
sulting from insulin resistance. Examination of blood con-
stituents (Figure 6C) revealed that the average glucose levels
of the treated mice was 70% lower than that of the untreated
mice (153.2 ± 30.5 versus 429.4 ± 87 mg/dl, respectively;
p = 0.003), which is in the range of normal glucose levels.
These results are consistent with the reported role of SREBP-
1c in the pathogenesis of hepatic insulin resistance (Ide et al.,
2004).
The serum level of total cholesterol showed a lower trend in
fatostatin-treated mice than in the control mice (183 ± 16 versus
219 ± 18 mg/dl, respectively; p = 0.06). However, there was a
significant decrease of approximately 35% in LDL (31 ± 3 mg/dl
versus 48 ± 8 mg/dl, respectively) and a lesser decrease of
approximately 22% in HDL (144 ± 11 mg/dl versus 183 ±
12 mg/dl, respectively) for the fatostatin-treated mice compared
with the control mice. Because there was a greater decrease in
the LDL serum levels than in the HDL serum levels of the fatos-
tatin-treated mice, this may be a desirable outcome following
treatment with fatostatin. The serum level of TGs increased
approximately 30% (115 ± 11 mg/dl versus 79 ± 12 mg/dl,
respectively) in the fatostatin-treated mice compared with the886 Chemistry & Biology 16, 882–892, August 28, 2009 ª2009 Elsevier Ltd All rights reserved
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A Small Molecule That Blocks Fat Synthesiscontrol mice, suggesting that fatostatin increases secretion and
mobilization of TG from the liver. The level of VLDL, which trans-
ports TGs, phospholipids, and cholesterol and is calculated
according to TG levels, increased approximately 50% (23.1 ±
2.31 mg/dl versus 15.8 ± 2.42 mg/dl, respectively) (Figure 6C).
It should be noted thatmice are a poormodel to investigate phar-
macological effects on cholesterol levels as statins generally are
not effective in reducing cholesterol levels in mice.
The serum level of the nonesterified fatty acids (NEFA) was
70% higher in the fatostatin-treated mice compared with the
controlmice (1.193 ± 0.261mEq/l versus 0.7 ± 0.2mEq/l, respec-
tively) (Figure 6C). This increase in NEFA levels may be caused
by increased lipolysis from adipose tissue, in response to an
increased demand for fatty acid oxidation. NEFA is known to be
associated with insulin resistance in both animals and human.
Although the serum levels of NEFA were elevated in the fatosta-
tin-treated mice, the glucose levels were significantly lower
than in the control mice, suggesting an improvement in insulin
sensitivity. It is interesting that ketonebodies (b-hydroxybutyrate)
increased approximately seven fold in the fatostatin-treated
mice compared with the control mice (3.62 ± 1.41 mg/dl versus
0.5 ± 0.37 mg/dl, respectively (Figure 6C). The high levels of
ketone bodies in the fatostatin-treatedmice suggest a significant
increase in fatty acid oxidation in the livers.We have also recently
shown that increased fatty acid oxidation in liver, adipose, and
muscle tissues in acetyl-CoA carboxylase 2 (acc2/) mutant
mice resulted in increased NEFA as well as higher ketone bodies
A B
C
Figure 6. Effects of Fatostatin on Body
Weight, Food Consumption, and Blood
Constituents of Male ob/ob Mice
(A) Representative control and fatostatin-treated
mice.
(B) Weight and cumulative food intake per mouse
during 28 days treatment.
(C) Blood constituents of control and fatostatin-
treated mice following treatment for 28 days
(mean ± SD; n = 5; *p < 0.05).
in the blood (Abu-Elheiga et al., 2001;
Abu-Elheiga et al., 2003; Oh et al., 2005).
Another phenotype of ob/ob mice is
excessive accumulation of fat in organs,
including nonalcoholic fatty liver. Livers
in the control ob/ob mice were enlarged,
and their pale color was evidence of fat;
the livers of the mice treated with fatosta-
tin appeared normal (Figure 7A). Livers of
the treated mice averaged approximately
32% lower in weight, and fat pads were
smaller, than those of the control mice
(Figure 7B). Oil Red-O section staining
showed that the livers of the control
mice contained abundant lipid droplets;
in contrast, the livers of the treated mice
contained lower levels of lipid accumula-
tion (Figure 7C). The TG and cholesterol
levels in the livers of the treated mice
were also reduced (Figure 7D). The
prevention of fatty liver by fatostatin in ob/ob mice is in agree-
ment with the reported role of SREBP-1 in developing fatty
liver: Transgenic mice overexpressing SREBP-1 developed fatty
livers (Horton et al., 2003b), while ob/ob mice lacking SREBP-1
(lepob/ob X Srebp 1/) had healthy livers (Yahagi et al., 2002).
The reduction of hepatic fat levels in the fatostatin-treated
mice was considered to be due to a decreased hepatic expres-
sion of SREBP-responsive lipogenic enzymes. Therefore, we
examined the effects of fatostatin on the hepatic protein levels
and enzymatic activities of representative SREBP-responsive
lipogenic enzymes, including FAS, ACC, stearoyl-CoA desatur-
ase 1 (SCD1), and ATP citrate lyase (ACL). Biochemical anal-
yses showed that protein levels and activities of the lipogenic
enzymes were reduced in liver extracts of fatostatin-treated
mice (Figures 7E, 7F, and 7G). The decrease in protein levels
can be attributed to a decrease in transcriptional or transla-
tional regulation. We used real-time PCR and determined the
levels of mRNA of representatives of lipogenic genes ACC1,
FAS, SCD1, HMG-CoA reductase (HMG-R), LDL receptor
(LDLR), and mevalonate pyrophosphate decarboxylase (MVD).
There was a reduction in the mRNA levels of these genes
(Figure 7H). These results, which are consistent with lower
levels of enzyme proteins and activities, indicate that fatostatin
lowers lipogenesis by inhibiting the maturation of SREBP. It
appears that fatostatin blocks the processing of SREBP in liver,
down-regulates lipogenic enzymes, and reduces hepatic TG
storage.Chemistry & Biology 16, 882–892, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 887
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Modulation of the SREBP pathway by small molecules is not
new. Researchers at GlaxoSmithKline have discovered small
molecules that activate SCAP/SREBP proteins and lower blood
cholesterol levels through the increased expression and activity
of the LDL receptor (Grand-Perret et al., 2001). Nevertheless, fa-
tostatin represents the first non-sterol-like synthetic molecule
that inhibits the activation of SREBPs. Both fatostatin and the
GlaxoSmithKline molecules appear to modulate the function of
SCAP/SREBP complex, resulting in distinct effects on the fatty
acid and/or cholesterol metabolism of experimental animals.
SCAP may be a key protein that is amenable to both positive
and negative control with simple synthetic molecules.
Our results of binding and cross-linking studies suggest that
fatostatin binds to SCAP at a distinct site from the sterol-binding
domain previously reported by Goldstein and co-workers
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Figure 7. Effects of Fatostatin on Liver and
Adipose Tissue of ob/ob Mice
(A) Representative livers of the fatostatin-treated
and control mice.
(B) The weight of livers and epididymal fat pads
from fatostatin-treated and control mice (mean ±
SD; n = 5; *p < 0.05).
(C) Sections of the livers of fatostatin-treated and
control mice showing Oil Red-O stained lipid
droplets.
(D) TGs and cholesterol levels in the livers of fatos-
tatin-treated and control mice (mean ± SD; n = 5;
*p = 0.0004; yp = 0.03).
(E) Activity of ACC and FAS were measured in liver
extracts of ob/ob mice (mean ± SD; n = 5; yp =
0.005; zp = 0.002).
(F) Western Blot analysis of liver crude extracts.
(G) Ratio of intensity of specific bands of different
lipogenic enzymes from fatostatin against control
mice after normalization to actin (mean ± SD; n =
5; *p < 0.05).
(H) Relative levels of mRNA of lipogenic enzymes
in livers of fatostatin-treated and control ob/ob
mice. RNA was isolated from both the fatostatin-
treated mice (n = 5) and the control mice (n = 5)
and measured by real-time RT-PCR, as described
elsewhere (Oh et al., 2005). The values were
normalized to actin and are depicted as means ±
SE (*p < 0.05).
(Adams et al., 2004). The fatostatin’s
mechanism for the modulation of the
SREBP-escorting function of SCAP is
likely to be distinct from that of sterols:
the binding site of fatostatin in SCAP is
different from that of sterols, and the
interaction does not induce the SCAP-
INSIG interaction. Further studies are
needed to determine the complete mech-
anism of action of fatostatin. One possi-
bility is that fatostatin may induce the
interaction of SCAP with unknown ER
proteins other than INSIGs. Alternatively,
fatostatin may directly affect the interac-
tion of SCAP with COPII proteins, which cluster the SCAP-
SREBP complex into coated vesicles that exit from the ER and
travel to the Golgi (Espenshade et al., 2002). PI3 kinase inhibitors
have been shown to inhibit ER-to-Golgi transport of SCAP
(Du et al., 2006). To test whether fatostatin acts through Akt to
control SCAP transport, we conducted a Western blot analysis
with anti-phospho-Akt antibody. Our data suggested that
fatostatin has no effect on phosphorylation of AKT (data not
shown).
Fatostatin was originally discovered in our laboratory as a
small molecule that generates two distinct phenotypes in cul-
tured mammalian cells: inhibition of the insulin-induced adipo-
genesis of 3T3-L1 mouse fibroblast cells and repression of the
serum-independent growth of DU145 human prostate cancer
cells. The first phenotype is in complete agreement with our
conclusion that fatostatin is a blocker of SREBPs because of
the known role of SREBP-1 in lipogenesis. The second effect888 Chemistry & Biology 16, 882–892, August 28, 2009 ª2009 Elsevier Ltd All rights reserved
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consistent with the inhibition of SREBPs, because the serum-
free medium lacks external fat sources. Without exogenous lipid
present in the serum, cells need to synthesize fatty acids and
cholesterol, the building blocks of membranes, to maintain the
cell growth. To test the importance of lipids in the cell growth,
the growth of the SREBP-1 knockdown cells was monitored in
a fat-free serum medium. The SREBP-1 silencing impaired the
cell growth in a fat-free medium as much as it did in the
serum-free IGF1-containingmedium (Figure S8). These observa-
tions suggest that fatostatin blocks the serum-independent
growth of cancer cells through the inhibition of SREBP-1.
To evaluate and validate the effectiveness of fatostatin in vivo,
and possibly identify other desirable phenotypes produced by
this small molecule, we studied its effect on an ob/ob obese
mouse model. An important discovery in the fatostatin-treated
mice was a reduction of both body weight and blood glucose
(Figure 6). The reduced body weight may be caused by a lower
lipogenesis rate, as a result of the down-regulation of lipogenic
enzymes such as ACC, FAS, ACL, and SCD1. Expression and
activities of these enzymes were significantly down-regulated
in fatostatin-treated mice, which resulted in lower levels of
long-chain fatty acid derivatives in their livers. In addition, the
reduction in malonyl-CoA—the product of ACC and a potent
inhibitor of carnitine palmitoyl transferase—may result in en-
hanced fatty acid oxidation and fat burning. We have shown
previously that acc2/mutantmice are lean and exhibit a higher
rate of fatty acid oxidation in muscle, liver, and adipose tissue,
and they have lower blood glucose levels (Abu-Elheiga et al.,
2001; Abu-Elheiga et al., 2003; Oh et al., 2005). Similar metabolic
profiles have been observed with peroxisome proliferator-acti-
vated receptor (PPAR) ligand treatment (Cho et al., 2008). We
tested whether fatostatin can serve as a ligand for PPARs (a,
g, and d). The results showed that fatostatin failed to activate
either PPAR at detectable levels, compared with known PPAR
ligands (Figure S9).
Our animal results support the notion that inhibition of SREBPs
by fatostatin down-regulates lipogenic enzymes, enhances fatty
acid oxidation, reduces weight, and increases insulin sensitivity,
which causes a lower level of glucose. Fatostatin or its analogs,
therefore, may serve as a chemical tool that provides insights
into the SCAP-mediated regulation of the SREBP pathway. Fa-
tostatin, or its analogs, may also become seed molecules for
pharmacological intervention in the metabolic syndrome. It
should be noted, however, that further studies with transgenic
animalsmay be needed to claim that themechanism of fatostatin
in vivo is the same as that in cultured cells.
SIGNIFICANCE
Fatostatin represents the first non-sterol-like synthetic
molecule that inhibits the activation of SREBPs, transcrip-
tion factors that play central roles in lipogenesis. Uncon-
trolled lipogenesis is implicated in a number of metabolic
diseases, including diabetes and cardiovascular diseases.
Major efforts are being devoted to target different players
in the fat metabolism. Fatostatin or its analogs may serve
a tool for gaining further insights into the regulation of
SREBP and fat metabolism.Chemistry & Biology 16, 8To our knowledge, fatostatin represents the first non-
sterol-like synthetic molecule that inhibits the activation
process of SREBPs. A molecular target of fatostatin is likely
to be SCAP just as that of sterols, endogenous inhibitors of
SREBPs. Interestingly, our results suggest that the binding
site of fatostatin in SCAP and its effects on the SCAP func-
tions are distinct from those of sterols. A complete under-
standing of the mechanism of action would provide insights
into how SREBPs can be regulated by small molecules.
Uncontrolled lipogenesis is implicated in a number of meta-
bolic diseases, including diabetes and cardiovascular
diseases. Major efforts are being devoted to target different
players in the fat metabolism. Considering the effects of fa-
tostatin in obese ob/ob mice described here and the chem-
ical tractability of this relatively simple molecule, fatostatin
may serve as a seed molecule for generating chemical tools
to analyze and control fat metabolism in whole animals.
EXPERIMENTAL PROCEDURES
Cell Culture
CHO-K1 cells were maintained in a Dulbecco’s modified Eagle’s medium/
Ham’s F12 medium [1:1] with 5% fetal bovine serum, 100 units/mL penicillin,
and 100 mg/mL streptomycin sulfate at 37C under 5% CO2. Human
androgen-independent prostate cancer (DU145) cells were maintained in an
Eagle’s minimum essential medium containing 2 mM L-glutamine, 1.0 mM
sodium pyruvate, 0.1 mM nonessential amino acids, and 1.5 g/L sodium bio-
carbonate with 10% fetal bovine serum, 100 units/mL penicillin, and 100 mg/
mL streptomycin sulfate at 37C under 5% CO2. 293T cells were maintained
in a Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum, 100
units/mLpenicillin, and 100mg/mL streptomycin sulfate at 37Cunder 5%CO2.
RT-PCR Experiments
Total RNAwas extracted fromDU145 cells in TRI reagent (Molecular Research
Center) and was isolated with an RNeasy Mini Kit (QIAGEN). The RNA sample
was subjected to RT-PCR by using the Access RT-PCR System (Promega).
RT-PCRs contained total RNA, 1 mM of each primer, 0.2 mM dNTP, 1 mM
MgSO4, AMV reverse transcriptase (2 units), and Tfl DNA polymerase (2 units)
in a final volume of 25 mL. The primer pairs used were as follows: 50-TCA GAC
CGGGAC TGC TTG GACGGC TCAGTC30 and 50-CCA CTT AGG CAG TGG
AAC TCGAAGGCCG30 for LDL receptor (LDLR); 50-GCC TGC TTGATA ATA
TAT AAA C30 and 50-CAC TTG AAT TGA GCT TTA G30 for stearoyl-CoA de-
saturase (SCD1); 50-AAG AAA AAG TGT CAG ACA GCT GG30 and 50-TGG
ACT GAA GGG GTG TTA GC30 for ATP citrate lyase (ACL); 50-GCC CGA
CAG TTC TGA ACT GGA ACA-30 and 50-GAA CCT GAG ACC TCT CTG AAA
GAG-30 for 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoAR); 50-CTG
CCTGAC TGCCTCAGC-30 and 50-ACC TCTCCTGACACC TGGG-30 for me-
valonate pyrophosphate decarboxylase (MVD); and 50-AAG ACT TCA GGG
TAA GTC ATC A-30 and 50-CGT GTA TAA TGG TGT CTA TCA G-30 for insulin
induced gene 1 (INSIG1). The amplification conditions were as follows: 1 cycle
at 94C for 4 min, then denatured at 94C for 40 s, annealed at 50C for 40 s,
and extended at 68C for 2 min with 22 cycles for SCD1 and HMG CoAR, an-
nealed at 58C with 24 cycles for LDLR and INSIG1, or annealed at 60C with
24 cycles for ACL, and annealed at 55Cwith 30 cycles for MVD. The amplified
DNAs were analyzed by an agarose gel and quantified with the Scion-image
software.
Luciferase Reporter Assay
On day 0, CHO-K1 cells were plated out onto a 96-well plate inmediumA (a 1:1
mixture of Ham’s F-12medium andDulbecco’smodified Eagle’smedium, with
5% fetal bovine serum, 100 units/mL penicillin, and 100 mg/mL streptomycin
sulfate). On day 2, the cells were transiently cotransfected with pSRE-Luc
(an SRE-1-driven luciferase reporter construct) (Hua et al., 1995) and pAc-b-
gal (b-gal reporter in which the expression of b-gal is controlled by an actin
promoter), using Lipofectamine reagent (Invitrogen). After incubation for 5 hr,82–892, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 889
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bated, in the absence or presence of fatostatin, in medium B (a 1:1 mixture
of Ham’s F-12 medium and Dulbecco’s modified Eagle’s medium, with 5%
lipid-depleted serum, 100 units/mL penicillin, 100 mg/mL streptomycin sulfate,
50 mM compactin, and 50 mM sodium mevalonate). After 20 hr of incubation,
the cells in each well were lysed, and aliquots were used to measure luciferase
and b-galactosidase activities. Luciferase activity was normalized by the
activity of b-galactosidase. For overexpression of the N-terminal matured
form of SREBP-1c, pCMV-SREBP-1c(1-436) was cotransfected with pSRE-
Luc and pAc-b-gal.
PLAP-BP2 Cleavage
On day 0, CHO-K1 cells were plated out onto a 96-well plate in medium A. On
day 2, the cells were transiently cotransfected with pCMV-PLAP-BP2(513–
1141), pCMV-SCAP, and pAc-b-gal, using Lipofectamine reagent (Invitrogen).
After incubation for 5 hr, the cells were washed with PBS and then incubated in
medium B, in the absence or presence of fatostatin (20 mM) or sterols (10 mg/
mL cholesterol and 1 mg/mL 25-hydroxycholesterol). After 20 hr of incubation,
an aliquot of the medium was assayed for secreted alkaline phosphatase
activity. The cells in each well were lysed and used for measurement of
b-galactosidase activities. The alkaline phosphatase activity was normalized
by the activity of b-galactosidase.
Western Blot Analysis of SREBP Processing
On day 0, CHO-K1 cells were plated out onto a 100 mm dish of medium A. On
day 2, the cells were washed with PBS, and then incubated in medium B in the
absence or presence of fatostatin. On day 3, the cells were washed once with
cold PBS, and then treated with buffer containing 10 mM Tris-HCl (pH 7.6),
100 mM NaCl, 1% (w/v) SDS, and protease inhibitor mixture (1 mg/mL pepsta-
tin A, 10 mg/mL leupeptin, and 200 mM phenylmethylsulfonyl fluoride). The
protein concentration of each total cell extract wasmeasured (BCA kit; Pierce),
after which a 22–33 mg aliquot of cell extract was mixed with 0.25 volume of
buffer (250 mM Tris-HCl [pH 6.8], 10% SDS, 25% glycerol, 0.2% [w/v] bromo-
phenol blue, and 5% [v/v] 2-mercaptoethanol) and heated for 7 min at 95C.
The samples were separated on a 10% SDS-PAGE gel and blotted, using
mouse monoclonal antibodies against SREBP-2 (IgG-7D4) (Yang et al.,
1995) or SREBP-1 (IgG-2A4) (Sato et al., 1994). The specific bands were
visualized using enhanced chemiluminescent (ECL) detection reagents
(Amersham).
Preparation of Cell Membrane Fraction
Cells were harvested, and then resuspended in buffer containing 10 mM
HEPES-KOH (pH 7.4), 10 mM KCl, 1.5 mM MgCl2, and 1 mM sodium EDTA,
then passed through a 22-gauge needle and centrifuged at 1,000 3 g for
5 min. The postnuclear supernatants were then centrifuged at 105 3 g for
30 min, and the supernatant was removed.
Modification of SCAP Oligosaccharides
Themembrane fraction of cell lysates was resuspended in 0.1 ml of buffer con-
taining 10mMHEPES$KOH (pH 7.4), 10mMKCl, 1.5mMMgCl2, 1 mM sodium
EDTA, and 100 mM NaCl. Aliquots of protein were then incubated in the
absence or presence of 1 mg of trypsin, in a total volume of 58 mL, for 30 min
at 30C. Reactions were stopped by the addition of 2 ml (400 units) of soybean
trypsin inhibitor. For subsequent treatment with endoglycosidase H, individual
samples received 10 ml of solution containing 3.5% (wt/vol) SDS and 7% (vol/
vol) 2-mercaptoethanol. After heating at 100C for 10 min, each sample
received sequential additions of 9 ml of 0.5 M sodium citrate (pH 5.5), 5 ml of
solution containing 17 3 protease inhibitors (a concentration of 13, corre-
sponding to 10 mg/mL leupeptin, 5 mg/mL pepstatin A, and 2 mg/mL aprotinin),
and 1 ml (5 units) of endoglycosidase H. The reactions were carried out over-
night at 37C, then stopped by the addition of 20 ml of buffer containing
0.25 M Tris-HCl (pH 6.8), 2% SDS, 10% (vol/vol) glycerol, 0.05% (wt/vol) bro-
mophenol blue, and 4%2-mercaptoethanol. Themixtures were then heated at
100C for 5 min and subjected to SDS/PAGE (12% gels).
Confocal Microscopic Analyses
CHO-K1 cells, on a glass-bottom 96-well plate (Grainer) at approximately 70%
confluency, were incubated for 1 hr with 0.2 mM ER-tracker Red (Invitrogen)890 Chemistry & Biology 16, 882–892, August 28, 2009 ª2009 Elsevand 5 mM dansyl fatostatin. Fluorescent images were captured and analyzed
with a Carl Zeiss LSM 510 confocal microscope, equipped with a CSU10 spin-
ning-disk confocal scanner (Yokogawa Electric Corporation) and an ORCA-
CCD camera (Hamamatsu Photonics). Images were analyzed with IPLab soft-
ware (Solution Systems).
Binding Assays
Themembrane fraction of cell lysates was extractedwith PBS containing 0.1%
FOS-Choline 10 (Hampton Research). The extract was mixed with Neutravi-
dine-agarose beads (10 mL) saturated with biotinylated fatostatin and was
incubated for 1 hr. The bound proteins were washed four times with PBS con-
taining 0.1% FOS-Choline 10, boiled in 25 ml of SDS sample buffer, and sub-
jected to Western blotting. For the competition assay, saturated amounts of
cholesterol or fatostatin were added to the membrane extract before incu-
bating with the beads.
Photo-Cross-Linking Assays
On day 0, 293T cells were plated out onto a 100 mm dish. On day 2, the cells
were transiently cotransfected with pCMV-SCAP-FLAG, pCMV-SCAP(1-415)-
FLAG, pCMV-SCAP(1-448)-FLAG, pCMV-SCAP(1-767)-FLAG, or pCMV-
SCAP(732-1276)-FLAG using FuGENE 6 reagent (Roche Applied Science).
On day 3, the cells were harvested, and FLAG-tagged full-length SCAP and
fragments of SCAP proteins were immunoprecipitated with 20 mg of anti-
FLAG IgG-M2 as described below. The pellets were then resuspended
50 mM of conjugate 5 in 100 ml of Nonidat P-40 lysis buffer, incubated for
0.5 hr, andwashed for 0.5 hr with 100 ml of Nonidat P-40 lysis buffer. The beads
were irradiated using a UV illuminator (UV Transilluminator, UVP) for 10 min
(365 nm for 2.5 min then 302 nm for 2.5 min, for a total of two sequences),
mixed with 53 SDS loading buffer, and boiled for 5 min. The obtained proteins
were subjected to SDS-PAGE and Western blot analysis with streptavidin-
HRP conjugate and anti-FLAG IgG-M2.
Coimmunoprecipitation of INSIG-1 with SCAP
On day 0, CHO-K1 cells were plated out onto a 100 mm dish of medium A. On
day 2, the cells were transiently cotransfected with pTK-HSV-SREBP-2,
pCMV-SCAP, and pCMV-INSIG-1-Myc (Yang et al., 2002; Yabe et al., 2002)
using FuGENE 6 reagent. On day 3, the cells were washed with PBS, and
then incubated in medium B in the absence or presence of fatostatin (20 mM)
or sterols (10 mg/mL cholesterol and 1 mg/mL 25-hydroxycholesterol). On day
4, the cells were washed once with cold PBS, and then suspended in 1 ml of
Nonidat P-40 lysis buffer containing 50 mM HEPES-KOH (pH 7.4), 100 mM
NaCl, 1.5 mM MgCl2, 0.1% (vol/vol) Nonidet P-40, and protease inhibitor
mixture (1 mg/mL pepstatin A, 10 mg/mL leupeptin, and 2 mg/mL aprotinin) in
the absence or presence of fatostatin (20 mM) or sterols (10 mg/mL cholesterol
and 1 mg/mL 25-hydroxycholesterol). The cells were lysed by passing through
a 22-gauge needle 15 times, and extracted for 1 hr at 4C. The cell extracts
were clarified by centrifugation at 1053 g for 30min. The supernatant was pre-
cleared for 1 hr by rotation with 50 ml of Protein G-Sepharose beads (GE
Healthcare UK Ltd.). Precleared lysates were rotated for 16 hr at 4C, with
20 mg of monoclonal anti-Myc IgG-9E10 together with 50 ml of protein G Se-
pharose beads. After centrifugation, the pelleted beads were washed for
15min at 4Cwith 1ml of Nonidat P-40 lysis buffer, in the absence or presence
of fatostatin (20 mM) or sterols (10 mg/mL cholesterol and 1 mg/mL 25-hydrox-
ycholesterol) four times. The pellets were then resuspended in 100 ml of buffer
containing 10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1% (wt/vol) SDS, and pro-
tease inhibitor mixture (1 mg/mL pepstatin A, 10 mg/mL leupeptin, and 2 mg/mL
aprotinin) and mixed with 53 SDS loading buffer containing 150 mM Tris HCl
(pH 6.8), 15% SDS, 25% (vol/vol) glycerol, 0.02% (wt/vol) bromophenol blue,
and 12.5% (vol/vol) 2-mercaptoethanol. The pellets were boiled for 5 min, and
subjected to SDS-PAGE and Western blot analysis with IgG-9D5 (SCAP) and
IgG-9E10 (INSIG-1).
Animal Studies Procedures
Four-to-five-week-old homozygous male obese (ob/ob) mice (C57BL/6J, The
Jackson Laboratory, Bar Harbor, ME) were housed under controlled condi-
tions (12 hr light/dark cycle; 25C) in the Animal Care Center at Baylor College
of Medicine. Animal experiments were conducted in accordance with the
Guide for the Care and Use of Laboratory Animals (NIH Publication No.ier Ltd All rights reserved
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access to standard laboratory chow (Purina Mills, Richmond, IN) and water for
one week after their arrival. On day 1 of the experiment, and every day there-
after, the weight and the amount of food intake of each mouse were measured
between 3:00 and 5:00 p.m. The treated mice then received an i.p. injection of
fatostatin (30 mg/kg; 150 mL) while the control mice received 10% DMSO in
PBS. Daily injections were continued for 28 days, when the study was ended.
Blood Constituents
After 28 days, fatostatin mice were fasted for 5–6 hr, and whole blood glucose
and b-hydroxybutyrate were measured with a Glucometer Precision Xtra
(Abbott). Measurements of the serum constituents glucose, TG, and choles-
terol were performed by the Comparative Pathology Laboratory (Baylor
College of Medicine). Serum nonesterified fatty acids (NEFA) were measured
using a NEFA C kit (Wako Chemicals, Richmond, VA).
Liver Analyses
Mice were sacrificed, and the weights of livers and epididymal fat pads were
determined. Frozen sections of liver slices from individual animals were
stained with Oil Red O, to visualize the fat droplet—TGs—as previously
described (Abu-Elheiga et al., 2001). The remaining liver tissues were frozen
in liquid nitrogen and kept at 80C for further analyses.
Tissue Triglyceride and Cholesterol Contents
Liver triglyceride and cholesterol contents were determined as described by
Chandler et al. (2003), using a Cholesterol E Kit (Wako) and an Infinity Triglyc-
eride Kit (Thermo Electron, Melbourne, Australia).
Enzymatic Activities and Western Blot Analyses
A portion of the frozen liver was ground to powder in liquid nitrogen. The
powder was suspended in 10 ml of PBS containing 0.1 mM PMSF, 5 mM ben-
zamidine, and 5 mg/mL protease inhibitor cocktail (Roche), and then homog-
enized using Polytron (33 30 s, at high speed) and sonicated briefly to degrade
DNA. The extracts were clarified by centrifugation at 16,0003 g for 20 min.
Protein concentrations in the supernatant were determined and subjected to
Western blot analysis using antibodies against FAS, ACC, SCD1, and ACL.
The intensities of the specific bands of proteins of interest were scanned
and normalized against b-actin for quantifications. FAS and ACC activities
from the liver extracts were determined as described earlier (Mao et al., 2006).
SUPPLEMENTAL DATA
Supplemental Data include nine figures and Supplemental Experimental
Procedures and can be found with this article online at http://www.cell.com/
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